



**HAL**  
open science

## Biocompatible Glyconanoparticles by Grafting of Sophorolipid Monolayers on Monodisperse Iron Oxide Nanoparticles

Andrea Lassenberger, Andrea Scheberl, Krishna Chaithanya Batchu, Viviana Cristiglio, Isabelle Grillo, Daniel Hermida Merino, Erik Reimhult, Niki Baccile

► **To cite this version:**

Andrea Lassenberger, Andrea Scheberl, Krishna Chaithanya Batchu, Viviana Cristiglio, Isabelle Grillo, et al.. Biocompatible Glyconanoparticles by Grafting of Sophorolipid Monolayers on Monodisperse Iron Oxide Nanoparticles. *ACS Applied Bio Materials*, 2019, 2 (7), pp.3095-3107. 10.1021/ac-sabm.9b00427 . hal-02164319

**HAL Id: hal-02164319**

**<https://hal.sorbonne-universite.fr/hal-02164319>**

Submitted on 25 Jun 2019

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

This document is confidential and is proprietary to the American Chemical Society and its authors. Do not copy or disclose without written permission. If you have received this item in error, notify the sender and delete all copies.

## Biocompatible Glyconanoparticles by Grafting of Sphorolipid Monolayers on Monodisperse Iron Oxide Nanoparticles

|                               |  |
|-------------------------------|--|
| Journal:                      | <i>ACS Applied Bio Materials</i>   |
| Manuscript ID                 | mt-2019-004275.R2  |
| Manuscript Type:              | Article  |
| Date Submitted by the Author: | 14-Jun-2019  |
| Complete List of Authors:     | Lassenberger, Andrea; Institut Laue-Langevin, Scheberl, Andrea; University of Natural Resources and Life Sciences Batchu, Krishna; Institut Laue-Langevin Cristiglio, Viviana; Institut Laue-Langevin, Grillo, Isabelle; Institut Laue-Langevin, Large Scale Structures Group Hermida-Merino, Daniel; Netherlands Organization for Scientific Research, Chemistry Reimhult, Erik; University of Natural Resources and Life Sciences Vienna, Department of Nanobiotechnology Baccile, Niki; CNRS-UPMC, LCMCP UPMC |
|                               |  |

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

# Biocompatible Glyconanoparticles by Grafting of Sophorolipid Monolayers on Monodisperse Iron Oxide Nanoparticles

*Andrea Lassenberger,<sup>a,b</sup> Andrea Scheberl,<sup>a</sup> Krishna Chaithanya Batchu,<sup>b</sup> Viviana Cristiglio,<sup>b</sup> Isabelle Grillo,<sup>b</sup> Daniel Hermida Merino,<sup>c</sup> Erik Reimhult,<sup>a,\*</sup> Niki Baccile<sup>d,\*</sup>*

<sup>a</sup>University of Natural Resources and Life Sciences Vienna, Institute for Biologically  
inspired materials, Department of Nanobiotechnology, Muthgasse 11/II, 1190 Vienna,  
Austria

\*erik.reimhult@boku.ac.at

<sup>b</sup>Institut Laue-Langevin, 71 Avenue des Martyrs, 38042 Grenoble Cedex 9, France

<sup>c</sup>ESRF – The European Synchrotron, 71 Avenue des Martyrs, 38042 Grenoble Cedex 9,  
France

1  
2  
3  
4 <sup>d</sup>Sorbonne Université, Centre National de la Recherche Scientifique, Laboratoire de  
5  
6  
7 Chimie de la Matière Condensée de Paris, LCMCP, F-75005 Paris, France  
8  
9

10  
11 \*niki.baccile@upmc.fr  
12  
13  
14  
15

16 KEYWORDS: sophorolipid, glyconanoparticle, nanoparticle surface functionalization,  
17  
18  
19 small angle neutron scattering, small angle X-ray scattering, lipid shell, iron oxide  
20  
21  
22  
23 nanoparticle, core-shell nanoparticle, colloidal stability  
24  
25  
26  
27  
28  
29  
30

31 ABSTRACT. This work presents synthesis and characterization of sophorolipid-coated  
32  
33  
34 monodisperse iron oxide nanoparticles. Sophorolipids are biological glycosylated  
35  
36  
37 amphiphiles produced by the yeast *S. bombicola*. In their open acidic form, sophorolipids  
38  
39  
40  
41 have been used as surface stabilizing agent for metal and metal oxide nanoparticles but  
42  
43  
44  
45 with poor control over size and structural properties. In this work, the COOH function of  
46  
47  
48  
49 sophorolipids (SL) was modified with nitrodopamine (NDA), a catechol known for its high  
50  
51  
52  
53 affinity to iron ions. The resulting new form of sophorolipid-nitrodopamide (SL-NDA) was  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 used as surface ligand for monodisperse iron oxide nanoparticles. We show, by a  
4  
5  
6  
7 combination of thermogravimetric analysis and small angle X-ray and neutron scattering,  
8  
9  
10 that iron oxide nanoparticles (IONP) are stabilized by a single, high-density SL-NDA layer,  
11  
12  
13  
14 which results in excellent colloidal stability under biologically relevant conditions such as  
15  
16  
17 high protein and salt concentration. The IONP grafted with SL-NDA showed negligible  
18  
19  
20 uptake and no cytotoxicity tested on two representative cell lines. Thus, they reveal the  
21  
22  
23 potential of sophorolipids as stable and non-toxic surface coatings for IONP-based  
24  
25  
26  
27  
28 biomedical and biotechnological applications.  
29  
30  
31  
32  
33  
34  
35  
36  
37

## 38 Introduction

39  
40

41 Superparamagnetic iron oxide nanoparticles are used in applications such as drug  
42  
43  
44 delivery, MRI or hyperthermia, for which iron oxide cores smaller than ~20 nm in diameter  
45  
46  
47 are coated with weakly adsorbed polymers (often dextran<sup>1-3</sup>) or lipids.<sup>4</sup> However,  
48  
49  
50  
51 physisorbed shells lead to low dispersant densities on the particle surface and low  
52  
53  
54  
55 colloidal stability over time. Controlled grafting of chemically linked dispersants yields  
56  
57  
58  
59  
60

1  
2  
3 denser and more stable shells; therefore, such approaches have received increasing  
4  
5  
6  
7 attention.<sup>5-6</sup> With improvements in the synthesis, monodisperse (SD < 5 %) iron oxide  
8  
9  
10 nanoparticles have been developed,<sup>7</sup> but their hydrophobic (mostly oleic acid) shell of  
11  
12  
13 weakly adhering ligands is not compatible with biomedical applications. Consequently,  
14  
15  
16  
17 the original ligands must be replaced by chemisorbed ligands that provide a water-soluble  
18  
19  
20  
21 and sterically stabilizing shell, crucial for colloidal stability in biological fluids. Ligand  
22  
23  
24 exchange protocols for highly hydrated and chemically grafted ligands, mainly based on  
25  
26  
27 poly(ethylene glycol) (PEG), have therefore been developed.<sup>8</sup> PEG provides excellent  
28  
29  
30  
31 colloidal stability and long circulation times of the particles in the body due to limited  
32  
33  
34 opsonization (protein binding and elimination of the particles by the reticuloendothelial  
35  
36  
37 system),<sup>9</sup> but PEG does not provide targeting specificity and has increasingly been  
38  
39  
40  
41 claimed to be subject to antibody production.<sup>10</sup> Coating of nanoparticles with biological or  
42  
43  
44 biomimetic ligands could address both these drawbacks; to this end, other surface ligands  
45  
46  
47  
48 are tested, including carbohydrates.

51  
52 Carbohydrate-grafted nanoparticles are generally referred to as glyconanoparticles<sup>11-12</sup>  
53  
54  
55  
56 and they are constituted by a nanoparticle core (e.g. gold or iron oxide) and a shell  
57  
58  
59  
60

1  
2  
3 composed of a glycoconjugate, a term which refers to a molecule composed of a  
4  
5  
6  
7 carbohydrate on one side and a binding group on the other. Since specific carbohydrates  
8  
9  
10 are known to selectively bind proteins,<sup>13-15</sup> glyconanoparticles generally contain  
11  
12  
13  
14 mannose, galactose, fucose or sialic acid, which are well-known saccharides targeting  
15  
16  
17 carbohydrate receptors on tumor cells.<sup>14, 16</sup> The binding group must be selected with the  
18  
19  
20 type of core particle surface in mind. Typically, thiols are used to graft to gold  
21  
22  
23  
24 nanoparticles while silanes are used to graft to oxide nanoparticles.<sup>12, 16-17</sup> The main  
25  
26  
27 drawback of these fully synthetic systems is the complex synthesis of the glycoconjugate  
28  
29  
30  
31 ligands, mainly due to the classically tedious sugar chemistry, and for this reason  
32  
33  
34  
35 alternative routes to prepare glyconanoparticles are worth exploring.  
36  
37

38  
39 In the past fifteen years, a number of research groups has shown the potential of using  
40  
41  
42 natural capping agents for metallic nanoparticles.<sup>18-19</sup> However, the field is still in its  
43  
44  
45  
46 infancy due to the poor control over both particle size distribution and composition of the  
47  
48  
49 shell. A promising group of novel capping agents are glycoconjugates obtained through  
50  
51  
52  
53 microbial synthesis. This class of molecules, in particular sophorolipids (SL), is the most  
54  
55  
56  
57 studied in the field of nanoparticle stabilization. SL are bolaform, non-toxic, bio-based  
58  
59  
60

1  
2  
3 glycolipids produced by the yeast *Starmerella bombicola* and characterized by a bulky  
4  
5  
6  
7 sophorose headgroup and a free carboxyl group.<sup>20</sup> SL are known to have natural targeting  
8  
9  
10 abilities, anti-cancer<sup>21</sup> and anti-bacterial<sup>22</sup> properties. SL were previously used to stabilize  
11  
12  
13 metal nanoparticles (Ag, Co)<sup>23-25</sup> and iron oxide nanoparticles (IONP).<sup>26</sup> The interaction  
14  
15  
16  
17 between SL and the nanoparticles was attributed to the complexing of the accessible  
18  
19  
20 COO<sup>-</sup> group to the surface; however, low grafting densities, poor control over  
21  
22  
23  
24 polydispersity, shell composition and even nanoparticle structure show that further  
25  
26  
27  
28 enhancement of SL-coated iron oxide nanoparticle synthesis and structure are required  
29  
30  
31 for applications. Here, we propose a new approach based on the use of size-controlled  
32  
33  
34 monodisperse IONP and SL having the COOH group modified with nitrodopamine (NDA)  
35  
36  
37  
38 via an amide bond. NDA is an anchor molecule that has been used to bind dispersants  
39  
40  
41 strongly to IONP.<sup>27-28</sup> We demonstrate grafting of a monolayer SL shell by a combination  
42  
43  
44  
45 of SANS and synchrotron SAXS. Furthermore, we show the resulting excellent colloidal  
46  
47  
48  
49 stability of the SL-IONP in physiological buffers and protein concentrations, paired with  
50  
51  
52  
53 absent cytotoxicity. This work opens opportunities for the application of glycosylated  
54  
55  
56 IONP obtained from natural glycoconjugates, combining strong colloidal stability and  
57  
58  
59  
60



1  
2  
3  
4 water solubility with the imaging, tracking and therapeutic abilities contributed by the  
5  
6  
7 IONP core.  
8  
9

## 12 Experimental Section

13  
14  
15  
16 **Materials.** All Chemicals were purchased from Sigma-Aldrich and all solvents from  
17  
18  
19 Roth. Chemicals were used as received without further purification (see supporting  
20  
21  
22 information for details). Sophorolipids (Sopholiance, batch number: 11103A, dry content:  
23  
24  
25  
26  $60 \pm 6$  %) are purchased from Soliance, France.  
27  
28  
29

30 **Synthesis of sophorolipids (SL).** Acidic sophorolipids have been prepared from a  
31  
32  
33 commercial batch of a sophorolipid mixture using alkaline hydrolysis to convert the crude  
34  
35  
36 lactonic/acidic mixture into a fully acidic sophorolipid compound. Extraction and  
37  
38  
39 purification have been performed using the method N°2 described earlier,<sup>29</sup> to which one  
40  
41  
42 should refer for a typical <sup>1</sup>H solution NMR fingerprint. The compound used here is majorly  
43  
44  
45 (> 80%) composed of the acidic subterminal C18:1-*cis* form that forms micelles.<sup>30</sup>  
46  
47  
48  
49  
50

51 **Synthesis of nitrodopamide-SL (SL-NDA) ligands.** 6-Nitrodopamine-hemisulfate (NDA-  
52  
53  
54 HSO<sub>4</sub>) was synthesized according to literature with slight modifications.<sup>31</sup> SL-NDA was  
55  
56  
57  
58  
59  
60

1  
2  
3 synthesized by (1-cyano-2-ethoxy-2-oxoethylideneaminoxy)dimethylamino-morpholino-  
4  
5  
6  
7 carbenium hexafluorophosphate (COMU) mediated peptide-coupling reactions.<sup>32-33</sup>  
8

9  
10 Briefly, 100 mg (0.16 mmol) of SL were pre-activated with 1.5 eq COMU and 1 eq *N*-  
11  
12 methylmorpholine in 7 mL dimethylformamide (DMF) at RT for 10 minutes. The mixture  
13  
14 was cooled to 0 °C and a mix of 1eq NDA and 1eq *N*-methylmorpholine in 5 mL DMF was  
15  
16  
17 slowly dropped to the activated acid. The mixture reacted for 1 h at 0 °C and subsequently  
18  
19  
20  
21  
22  
23  
24 3 h at RT. The solvent was evaporated and 4 mL of Milli-Q were added to the crude  
25  
26  
27  
28 product. The product was transferred into butanol (BuOH) and extracted thrice with Milli-  
29  
30  
31 Q, once with 1.5 M HCl and finally washed with pure Milli-Q. BuOH was evaporated and  
32  
33  
34 the product was vacuum-dried. The coupling of SL to NDA was confirmed by FTIR and  
35  
36  
37 by solution <sup>1</sup>H NMR (see Figure S1 for details), showing the coexisting 1:1 ratio between  
38  
39  
40  
41  
42 SL and NDA together with the downfield shift, from 3.05 ppm to 3.47 ppm, attributed to  
43  
44  
45 the  $\alpha$ -CH<sub>2</sub> in NDA and respectively in an amine and amide environment.<sup>32, 34</sup> One can  
46  
47  
48 also observe the parallel upfield shift, from 2.30 ppm to 2.18 ppm of  $\alpha$ -CH<sub>2</sub> in SL for  
49  
50  
51  
52 respectively an amine and an amide environment. NMR excludes the presence of  
53  
54  
55 unreacted free NDA, but we must acknowledge the presence of residual COMU and  
56  
57  
58  
59  
60

1  
2  
3 unreacted SL (between 10 and 20 mol% with respect to SL-NDA), which due to similar  
4  
5  
6  
7 physico-chemical properties were not removed by washing the sample. However, COMU  
8  
9  
10 and unreacted SL do not have the affinity to the iron oxide nanoparticle surface to displace  
11  
12  
13  
14 oleic acid or interfere with the ligand displacement by SL-NDA.  
15  
16

17 **Synthesis of iron oxide nanoparticles (IONP).** Iron oxide NP (3-10 nm in diameter)  
18  
19  
20 coated with oleic acid (OA) were synthesized by thermal decomposition of iron  
21  
22  
23 pentacarbonyl according to a heat-up procedure originally proposed by Hyeon *et al.*<sup>35</sup> that  
24  
25  
26  
27 was slightly modified as described in <sup>8</sup>. Details for the molar ratios of reactants can be  
28  
29  
30  
31 found in the supporting information (Table S1). Larger, 14.1 nm IONP were synthesized  
32  
33  
34  
35 via a modified two-step method introduced first by Park *et al.*<sup>36</sup> and previously by us.<sup>9</sup>  
36  
37  
38 IONP cores with diameters of 3.1, 4.6 and 14.1 nm were used for functionalization with  
39  
40  
41  
42 sophorolipids and further experiments.  
43  
44

45 **Ligand exchange and purification.** SL-IONP were synthesized according to a slightly  
46  
47  
48 modified method published earlier.<sup>8</sup> For 4.6 nm cores, 0.9 g of as-synthesized IONP  
49  
50  
51  
52 coated with oleic acid were dispersed in 20 mL DMF. 0.183 g of SL-NDA were added and  
53  
54  
55  
56 the mixture was sonicated for 28 h at slightly elevated temperature. Amounts of ligand  
57  
58  
59  
60

1  
2  
3 were adjusted for the smaller 3.1 nm IONP to account for the difference in surface area  
4  
5  
6 and the same surface area to ligand ratio was used. However, for the 14.1 nm cores we  
7  
8  
9  
10 used a much larger excess of ligand (10x with respect to surface area), supposing that a  
11  
12  
13 larger excess of ligand will aid in achieving a high surface coverage. After ligand  
14  
15  
16  
17 exchange, the SL-IONP were washed three times with n-hexane to remove released OA.  
18  
19  
20  
21 In a final step, the solvent was evaporated and the IONP were lyophilized. The lyophilized  
22  
23  
24 SL-IONP were redispersed in Milli-Q and dialysed in a 12-14 kDa MWCO dialysis bag  
25  
26  
27  
28 against 5 L Milli-Q to remove excess SL-NDA ligands. Alternatively, SL-IONP were  
29  
30  
31 purified by repeated (5x) membrane centrifugation in 50 kDa MWCO Amicon filter units.  
32  
33  
34  
35 The purified SL-IONP were lyophilized and could be stored for more than two years as a  
36  
37  
38 dark-brown powder. The yield was 96 % calculated with respect to the initial amount of  
39  
40  
41 IONP cores. SL-IONP were analyzed by TEM, TGA, ATR-FTIR and DLS.  
42  
43  
44

45 The samples were named according to their core diameter measured by TEM: 3.1 nm  
46  
47  
48 SL-IONP (diameter 3.1 nm), 4.6 nm SL-IONP (diameter 4.6 nm) and 14.1 nm SL-IONP  
49  
50  
51 (diameter 14.1 nm)  
52  
53

54  
55  
56 **Cell growth.** U937 cells were grown under conditions reported in <sup>9</sup>.  
57  
58  
59

1  
2  
3 **Toxicity test.** Toxicity measurements were performed with the PrestoBlue® Cell Viability  
4  
5  
6  
7 assay. Briefly,  $2 \times 10^4$  cells were seeded on 96-well plates using 200  $\mu$ l medium per well  
8  
9  
10 and incubated for 16 h (each 6 repeats for sample and control). 5  $\mu$ l nanoparticle  
11  
12  
13 dispersion (1 mg Fe/ml) were added and incubated for either 2 or 20 h. As control 5  $\mu$ l  
14  
15  
16 Milli-Q water were added. After incubation, 20  $\mu$ l PrestoBlue® were added and plates were  
17  
18  
19 incubated for one hour. A Tecan infinite F200 plate reader with excitation filter  $560 \pm 20$   
20  
21  
22 nm and emission filter  $595 \pm 35$  nm was used to read the plates. The background was  
23  
24  
25  
26  
27 determined by measuring medium with presto blue at 10 % (v/v).  
28  
29  
30

31 Viability was calculated as:  
32  
33

$$\frac{X}{X_c} * 100 \% \quad (1)$$

34  
35  
36  
37  
38  
39

40 with  $X$  the average value determined for cells incubated with SL-IONP and  $X_c$  the  
41  
42  
43 average value measured for control cells.  
44  
45  
46

47 **SL-IONP uptake by cells and iron quantification.** For uptake experiments,  $2 \times 10^6$  cells  
48  
49  
50 (monocytes) and  $1 \times 10^6$  cells (MCF-7) were seeded in a total volume of 5 ml in 6-well  
51  
52  
53 plates and incubated for 12 h. 50  $\mu$ L of a 1 mg/mL Fe dispersion of SL-IONP were added  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 and the cells were incubated for 20 hours. The control well was incubated with 50  $\mu$ L Milli-  
4  
5  
6  
7 Q water. After incubation, cells were centrifuged and consequently washed three times  
8  
9  
10 with PBS to remove IONP that were not taken up the cells. Iron quantification was done  
11  
12  
13 by a modified Ferrozine test as described previously.<sup>9</sup> For each type of SL-IONP at least  
14  
15  
16  
17 5 wells were prepared in parallel and 3 independent repetitions were performed, resulting  
18  
19  
20  
21 in a minimum of 9 data points for each type of SL-IONP.  
22  
23

24 **Protein quantification.** The Roti<sup>tm</sup>-NanoQuant protein detection assay was used for  
25  
26  
27 protein quantification according to the manufacturer's protocol. BSA dissolved in 50 mM  
28  
29  
30 NaOH was used as a standard.  
31  
32  
33

34  
35 **Transmission electron microscopy (TEM) and analysis.** TEM images were recorded on  
36  
37  
38 a FEI Tecnai G2 20 transmission electron microscope at 160 kV for low resolution and  
39  
40  
41 200 kV for high resolution imaging. Samples were drop-casted from toluene dispersions  
42  
43  
44 (IONP capped by oleic acid) or aqueous dispersions (SL-IONP) onto a 300-mesh carbon-  
45  
46  
47 coated copper. The Pebbles<sup>37</sup> software package was used to determine the size  
48  
49  
50  
51 distributions from the micrographs. Approximately 900 IONP were used for size  
52  
53  
54  
55 determination by Pebbles for each sample of nanoparticles.  
56  
57  
58  
59  
60

1  
2  
3  
4       **Transmission Electron Microscopy experiments under cryogenic conditions (cryo-**  
5  
6  
7 **TEM).** Cryo-TEM images were recorded on a FEI Tecnai 120 twin microscope at 120 kV  
8  
9  
10 with a Gatan Orius CCD numeric camera and a Gatan Cryoholder (Gatan 626DH, Gatan).  
11  
12  
13 DigitalMicrograph™ software was used for image acquisition. A custom-built device was  
14  
15  
16 used for cryo-fixation. SL-IONP aqueous dispersions and SL-NDA solutions were  
17  
18  
19 deposited on glow-discharged holey carbon copper grids (Quantifoil R2/2, Germany). The  
20  
21  
22 grids were immediately plunge-freezed by dipping into liquid ethane at -180 °C and  
23  
24  
25 transferred into liquid nitrogen. All grids were stored in liquid nitrogen.  
26  
27  
28  
29  
30

31       **Thermogravimetric Analysis (TGA).** TGA data were measured using a Mettler-Toledo  
32  
33  
34 TGA/DSC 1 STAR System in a temperature range of 25-650 °C with 10 K/min. A stream  
35  
36  
37 of 80 mL/s of synthetic air was used to ensure complete combustion of the SL-NDA  
38  
39  
40 ligands since NDA is known to polymerize by pyrolysis under N<sub>2</sub>. 0.5 - 1.5 mg sample  
41  
42  
43 were measured, The total organic content (TOC) was calculated as the fraction of mass  
44  
45  
46 loss up to 650 °C.  
47  
48  
49  
50  
51

52       **Dynamic Light Scattering (DLS).** DLS was measured on a Malvern Zetasizer Nano-ZS  
53  
54  
55 at 20 °C. Instrument settings: Fe<sub>3</sub>O<sub>4</sub>, Milli-Q as dispersant (0.89 mPa·s, RI=1.33), 3  
56  
57  
58  
59  
60

1  
2  
3 individual measurements were performed with 13 runs of 10 s each. All samples of SL-  
4  
5  
6  
7 IONP were measured at a concentration of 0.5 mg<sub>Fe</sub>/mL. The nanoparticles were  
8  
9  
10 dispersed in water (2 mg/mL) and 10 % fetal calf serum for experiments in which the  
11  
12  
13 temperature was varied from 20 °C to 70 °C and back with 5 °C steps and an equilibration  
14  
15  
16 time of 2 minutes. At each temperature, 3 individual measurements with 13 runs of 10 s  
17  
18  
19  
20  
21 were recorded.  
22  
23

24 **<sup>1</sup>H Nuclear magnetic resonance (NMR) measurements.** <sup>1</sup>H NMR data were acquired on  
25  
26  
27 a Bruker Avance III 300 spectrometer using a 5 mm <sup>1</sup>H-X BBFO probe, 16 transients with  
28  
29  
30 1 s recycling delay. The value chemical shifts (δ) are reported in ppm at 298 K using  
31  
32  
33 tetramethylsilane (TMS) as reference. MeOD-d<sub>4</sub> was used as solvent. COSY spectra  
34  
35  
36 were acquired using a standard pulse program from the Avance III library, with 1 s  
37  
38  
39 recycling delay, 8 transients per scan and 256 spectra acquired in the F1 dimension.  
40  
41  
42  
43  
44  
45  
46  
47  
48

49 **Attenuated total reflection – Fourier transform infra-red (ATR-FTIR) measurements.** IR  
50  
51  
52 spectra of the lyophilized samples were recorded on a Perkin Elmer 400 FTIR  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 spectrometer with diamond single-reflection ATR equipment and a resolution of  $4\text{ cm}^{-1}$ ,  
4  
5  
6  
7 averaging 32 scans.  
8  
9

10 **Small Angle X-ray Scattering (SAXS).** SAXS patterns were measured using a Dectris-  
11  
12 Pilatus 1M detector with a resolution of  $981 \times 1043$  pixels and a pixel size of  $172 \times 172$   
13  
14  $\mu\text{m}$  at the Dutch-Belgian Beamline (DUBBLE) station BM26B of the European  
15  
16  
17 Synchrotron Radiation Facility (ESRF) in Grenoble, France. The sample to SAXS detector  
18  
19  
20  
21 distance was set to ca. 3100 mm using a wavelength of  $1.033\text{ \AA}$ . SAXS patterns were  
22  
23  
24  
25 integrated azimuthally to obtain a typical  $I(q)$  spectrum. A quartz capillary, used as  
26  
27  
28  
29 sample holder, was filled with Milli-Q grade water, used as solvent, and then with the  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
standard sample ( $d_{ref} = 58.38\text{ \AA}$ )

1  
2  
3 **Small Angle Neutron Scattering (SANS).** SANS was performed at the Institut Laue-  
4 Langevin (ILL, Grenoble, France) on D16 and D33 beamlines. The spectrometer  
5  
6 configurations were adjusted as follows. *D16 beamline* ( $3.5 \cdot 10^{-2} \text{ \AA}^{-1} < q < 0.5 \text{ \AA}^{-1}$ ): neutron  
7 wavelength,  $\lambda = 4.5 \text{ \AA}$ , sample-to-detector distance = 955 mm, sample and detector  
8  
9 rotation angles:  $\omega = 5.5^\circ$  and  $2\theta = 11^\circ$ , acquisition time = 60 min. *D33 beamline* ( $5.0 \cdot 10^{-3}$   
10  
11  $\text{ \AA}^{-1} < q < 0.3 \text{ \AA}^{-1}$ ): neutron wavelengths:  $\lambda_1 = 4.6 \text{ \AA}$  and  $\lambda_2 = 13.0 \text{ \AA}$  sample-to-detector  
12  
13 distances = 2 m, 10 m, acquisition time = 10 min (in D<sub>2</sub>O), 45 min (in MeOD-d4). For both  
14  
15 spectrometers: neutron absorber: Boron Carbide (B<sub>4</sub>C), thickness of quartz Hellma cells:  
16  
17 1 mm, temperature (controlled):  $T = 25^\circ\text{C}$ , background: 99.9 % D<sub>2</sub>O. Direct beam, empty  
18  
19 cell and H<sub>2</sub>O were also recorded for both spectrometers. The background sample (D<sub>2</sub>O)  
20  
21 signal was subtracted from the experimental data.  $q$  is defined as  $(4\pi/\lambda)\sin\vartheta/2$  where  $\vartheta$   
22  
23 is the scattering angle between the incident and the scattered neutron beams. Data  
24  
25 treatment was done with the home-made software package provided at the beamline.  
26  
27 Direct determination of the number of neutrons in the incident beam and the detector cell  
28  
29 solid angle allowed obtaining absolute values of the scattering intensity. The acquired 2-  
30  
31 D raw data were corrected for the scattering of the ambient background and the empty  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 cell. Further, the data were normalized by the neutron flux on the samples to yield an  
5  
6  
7 absolute scale (cross section per unit volume). The data were radially averaged to yield  
8  
9  
10 the 1-D intensity distribution  $I(q)$ .  
11  
12

13  
14 **Fit of small angle scattering data (SAXS, SANS).** All data presented were fitted using a  
15  
16  
17 classical core-shell sphere form factor model (assuming a unitary structure factor in the  
18  
19  
20 analyzed range of  $q$ -values),<sup>38</sup> using the SasView 3.1.2 software (CoreShellModel)  
21  
22  
23 available free of charge on the developers' website.<sup>39</sup> In the model, we consider the core  
24  
25  
26 to be composed of iron oxide and the shell of a homogeneous SL-NDA layer of variable  
27  
28  
29 thickness. One should be aware that this is a strong approximation, because SL-NDA  
30  
31  
32 could be described by at least three different regions of inequivalent densities: sophorose,  
33  
34  
35 oleic acid and NDA. Nonetheless, the goal of the fitting analysis in this work is not to  
36  
37  
38 precisely describe the morphology of the of the nanoparticle shell, but to demonstrate that  
39  
40  
41  
42 SL-IONP have a shell with a thickness compatible with a monolayer of SL-NDA; the  
43  
44  
45 homogeneous core-shell model provides an adequate model with a minimum number of  
46  
47  
48 fitting variables to determine the presence and thickness of a reasonably homogeneous  
49  
50  
51  
52 shell. All theoretical and technical details of both the model and fitting function can be  
53  
54  
55  
56  
57  
58  
59  
60

found at on the developers' homepage.<sup>39</sup> The following parameters (Table 1) characterize the fitting function:

**Table 1.** Structural parameters used in the core-shell sphere model to fit both the SANS and SAXS data recorded for the SL-IONP.

| Parameter     | Description  | Fixed | Variable |
|---------------|--|-------|----------|
| $d$           | Core diameter  | x     |          |
| $t$           | Shell Thickness  |       | x        |
| $\rho_c$      | Scattering Length Density (SLD) of the IONP core   | x     |          |
| $\rho_s$      | Scattering Length Density (SLD) of the SL shell  |       | x        |
| $\rho_{solv}$ | Scattering Length Density (SLD) of the solvent (H <sub>2</sub> O and D <sub>2</sub> O for X-ray and neutron scattering experiments respectively) | x     |          |
| scale         | Volume fraction  | x     |          |
| background    | Background level   |       | x        |
| PDI           | Polydispersity   |       | x        |

The fixed parameters of the fitting function vary according to the type of technique used to study the samples. The fixed values which we have used in this work are reported

hereafter. The nanoparticle diameter  $d$  is determined independently by TEM and SAXS.

The SLD values have been determined using the SLD calculator tool in the SasView

software.  $\rho_{solv}(\text{X-ray}) = 9.410 \times 10^{-6} \text{ \AA}^{-2}$  and  $\rho_{solv}(\text{neutron}) = 6.4 \times 10^{-6} \text{ \AA}^{-2}$ , where  $\rho_{solv}(\text{X-}$

ray) and  $\rho_{solv}(\text{neutron})$  respectively refer to the X-ray and neutron SLD of  $\text{H}_2\text{O}$  and  $\text{D}_2\text{O}$ .  $\rho_c$

(X-ray) =  $40.0 \times 10^{-6} \text{ \AA}^{-2}$  and  $\rho_c(\text{neutron}) = 6.9 \times 10^{-6} \text{ \AA}^{-2}$  refer to the X-ray and neutron

SLD of iron oxide respectively, for which we have used the bulk density value of 5.17

$\text{g.cm}^{-3}$ . Polydispersity was allowed to vary between 0.1 and 0.15 and the volume fraction

was set to 0.4 % for samples 3.1 nm SL-IONP and 4.6 nm SL-IONP and to 0.1 % for

sample 14.1 nm SL-IONP, the smaller value coming from the larger amount of SL-NDA

in the 14.1 nm SL-IONP sample (please refer to main text for more details). In the final

fitting procedure,  $t$  and  $\rho_s$  are the only structural variable parameters, while the

background level is set as variable mainly to adjust the quality of the final fit. The typical

size and composition of SL-NDA also imposes several constraints on the effective  $t$  and

$\rho_s$  values. One can reasonably consider  $2.0 < t \text{ (nm)} < 3.5$  for a single SL-NDA layer,

where the lower and upper limits consider plausible molecular bending and stretching;

meanwhile,  $9.6 < \rho_s \text{ (X-ray)} (10^{-6} \text{ \AA}^{-2}) < 12$  and  $1 < \rho_s \text{ (neutron)} (10^{-6} \text{ \AA}^{-2}) < 5$  reasonable


1  
2  
3 identify the range for both the X-ray and neutron shell SLD values, which can vary  
4  
5  
6  
7 between a highly hydrated shell and a poorly hydrated organic layer.  
8  
9

## 14 Results and Discussion

15  
16  
17 **IONP synthesis, ligand exchange and purification.** Spherical, monodisperse and single-  
18  
19  
20 crystalline iron oxide nanoparticles with diameters of  $3.1 \pm 0.3$  nm ( $\sigma = 8.0$  %),  $4.6 \pm 0.3$   
21  
22  
23 nm ( $\sigma = 7.0$  %) and  $14.1 \pm 0.9$  nm ( $\sigma = 6.9$  %) were synthesized and characterized by  
24  
25  
26  
27 HR- and LR-TEM. Figure S2 shows TEM micrographs of as-synthesized monodisperse  
28  
29  
30  
31 oleic acid-coated iron oxide cores.  
32  
33

34  
35 The exchange of hydrophobic oleic acid for sophorolipid-nitrodopamide ligand was  
36  
37  
38 performed using a method established earlier<sup>8</sup> and yielded well-dispersed SL-NDA  
39  
40  
41 coated IONP (SL-IONP) with three different core sizes (Figure 1). Single-crystallinity of  
42  
43  
44 the IONP cores was revealed by HR-TEM (inset in Figure 1C and Figure S3) and the  
45  
46  
47 lattice spacing in the (220) direction was measured to be 0.29 nm. The electron diffraction  
48  
49  
50 pattern (inset Figure 1B) shows the high crystallinity of the IONP. The determined ratios  
51  
52  
53 of  $d$ -spacings show good agreement with the JCPDS database values given for  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 maghemite or magnetite.<sup>40</sup> Single-crystalline iron oxide nanoparticles (magnetite and  
4  
5  
6  
7 maghemite) in this size-range are known to be superparamagnetic, thereby possessing  
8  
9  
10 attractive properties for biomedical imaging and drug delivery.  
11  
12  
13  
14  
15



31  
32 **Figure 1.** TEM micrographs of three sizes of SL-IONP of sizes A)  $3.1 \pm 0.3$  nm, B)  $4.6 \pm$   
33  
34  $0.3$  nm and C)  $14.1 \pm 0.9$  nm. The insets in B) and C) show the electron ring diffraction  
35  
36 pattern and a high-resolution micrograph of 14.1 nm IONP, revealing the high crystallinity  
37  
38 of the single crystal cores.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49

50  
51 To demonstrate colloidal stability of SL-grafted IONP, excess ligand should be removed  
52  
53  
54 from the nanoparticle dispersion. Thus, SL-IONP were purified using two common  
55  
56  
57  
58  
59  
60

1  
2  
3 purification methods for nanoparticles, namely dialysis and membrane centrifugation to  
4  
5  
6  
7 remove the excess of the micelle-forming glycolipid ligand.  
8  
9

10 The functionalization of the IONP with SL-NDA through ligand replacement was first  
11  
12 evaluated using ATR-FTIR. Figure 2 shows the FTIR spectra of the compounds and  
13  
14 products. NDA has a characteristic C-O stretch band at  $1272\text{ cm}^{-1}$ ,<sup>41</sup> which can be found  
15  
16  
17 in the product of the purified SL-NDA but not in pure SL. Likewise, the “sugar bands”  
18  
19  
20 corresponding to C-O and C-O-C stretch modes at  $1021\text{ cm}^{-1}$  and  $1069\text{ cm}^{-1}$ ,<sup>42</sup>  
21  
22  
23 respectively, from the sophorolipid are also strong in the SL-NDA product. Finally, the  
24  
25  
26 bands of the amide bond formed between SL and NDA are clearly visible in SL-NDA.  
27  
28  
29  
30  
31  
32  
33  
34  
35 Figure 2 shows that two characteristic bands of oleic acid, the C=O stretch at  $1707\text{ cm}^{-1}$   
36  
37  
38 (which is slightly higher than for sophorolipid) and the out-of-plane O-H stretch at  $963$   
39  
40  
41  
42  $\text{cm}^{-1}$  are absent or insignificant compared to the characteristic bands of the sophorolipid  
43  
44  
45 and NDA.<sup>32</sup> In summary, the ATR-FTIR results strongly support successful ligand  
46  
47  
48  
49 replacement of the oleic acid by SL-NDA to form iron oxide nanoparticles with a shell of  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000






Figure 2 ATR-FTIR spectra of as-synthesized IONP (oleic acid capped, green), nitrodopamine (grey), sophorolipid-NDA (blue), SL-IONP 4.6 nm (red) and sophorolipid (black). Curves have been shifted vertically for clarity. With attributions:  $\delta_{(C=O)-OH}$  (oleic acid): 963  $\text{cm}^{-1}$ ,  $\nu_{C-O}$  (sugar): 1021 and 1069  $\text{cm}^{-1}$ ,  $\nu_{C-O}$  (catechol): 1272  $\text{cm}^{-1}$ ,  $\nu_s(\text{NO}_2)$ : 1331  $\text{cm}^{-1}$ ,  $\nu_{C-C}$  (catechol): 1507  $\text{cm}^{-1}$ ,  $\nu_a(\text{NO}_2)$ : 1538  $\text{cm}^{-1}$ ,  $\nu_{C=O}$  (amide): 1643  $\text{cm}^{-1}$ ,  $\nu_{C=O}$  (amide) and  $\delta_{N-H}$  (amide): 1538  $\text{cm}^{-1}$  and ,  $\nu_{C=O}$  (carboxylic): 1707  $\text{cm}^{-1}$ .<sup>41-43</sup>

1  
2  
3  
4 The average grafting density of SL-NDA ligand irreversibly bound to the Fe-ions at the  
5  
6  
7 IONP surface was evaluated after purification by TGA. Typical TGA weight loss profiles  
8  
9  
10 for 3.1 nm SL-IONP, 4.6 nm SL-IONP and 14.1 nm SL-IONP are shown in Figure S4. The  
11  
12  
13 total organic content (TOC) was determined as the fraction of mass loss up to 650 °C. If  
14  
15  
16  
17 all excess ligand is removed, the TOC can be converted into the dispersant grafting  
18  
19  
20  
21 density using the known molecular weight of SL-NDA, the defined average iron oxide core  
22  
23  
24 area determined by TEM and a known iron oxide core density of 5.17 g/cm<sup>3</sup>. We thus  
25  
26  
27  
28 assume for this calculation that all oleic acid was replaced by SL-NDA during the rigorous  
29  
30  
31  
32 ligand replacement and purification. Earlier studies have shown that ligand replacement  
33  
34  
35 of OA by hydrophobic ligands is challenging and can leave significant residues within the  
36  
37  
38 nanoparticle shell.<sup>32, 44</sup> If this is the case, the amount of SL-NDA grafted to the IONP  
39  
40  
41  
42 would be overestimated. However, we have previously investigated the ligand  
43  
44  
45 replacement and purification protocol used here and shown that the amount of residual  
46  
47  
48  
49 OA is below the detection limit by ATR-FTIR. As discussed above, the ATR-FTIR data  
50  
51  
52 shown in Figure 2 supports this finding. Additionally, the calculation of the grafting density  
53  
54  
55  
56 based on the TGA data can yield a higher value than the actual grafting density if there  
57  
58  
59  
60

1  
2  
3 is also free ligand present in a sample. We therefore list the average number of ligands (  
4  
5  
6  
7  $n_{ligands}$ ) per  $\text{nm}^2$  in Table 2 calculated in the same way for differently sized IONP purified  
8  
9  
10 by dialysis or membrane centrifugation (Amicon 50 kDa MWCO) to take into account the  
11  
12  
13 possible presence of free ligand.  
14  
15  
16  
17  
18  
19  
20  
21

22 **Table 2.** TGA results for SL-IONP of three different core sizes. Total organic contents  
23  
24  
25 (TOC) was converted into average number of ligands/ $\text{nm}^2$  ( $n_{ligands}/\text{nm}^2$ ) using the known  
26  
27  
28 SL-NDA Mw (902 g/mol).  
29  
30  
31  
32

| SL-IONP type              | $n_{ligands}/\text{nm}^2$ [dispersant/ $\text{nm}^2$ ] | TOC [%w/w]        |
|---------------------------|--|-------------------|
| 3.1 ± 0.3 nm<br>dialyzed  | 8.0 <sup>a</sup>                                       | 82.3 <sup>a</sup> |
| 3.1 ± 0.3 nm Amicon       | 7.1 <sup>a</sup>                                       | 80.5 <sup>a</sup> |
| 4.6 ± 0.3 nm<br>dialyzed  | 4.3  | 60.8              |
| 4.6 ± 0.3 nm Amicon       | 3.3  | 55.6              |
| 14.1 ± 0.9 nm<br>dialyzed | 37.4 <sup>a</sup>                                      | 82.1 <sup>a</sup> |

1  
2  
3  
4 14.1 ± 0.9 nm  
5 Amicon 45.2<sup>a</sup> 84.8<sup>a</sup>  
6  
7

---


8 <sup>a</sup> Samples contained large amounts of excess ligand.  
9  
10  
11  
12  
13

14 The limiting factor for ligand adsorption to the IONP surface is given by the number of  
15 surface iron sites (3.5 - 5.9 depending on crystal plane)<sup>45</sup> or the spatial requirements  
16 (footprint) of the ligand. The hydrated sugar headgroup and the unsaturated fatty acid  
17 structure of SL could sterically hinder achieving the maximum grafting density of NDA,  
18 but this steric blocking is reduced by the high curvature of the IONP that provides much  
19 larger volume for the headgroup than for the binding group. The grafting density of the  
20 deacetylated acidic form of sophorolipids (the same used in this work) varies according  
21 to the system under study; one finds between 2 and 3 molecules/nm<sup>2</sup> on a flat gold  
22 surface (evaluated by X-ray photoelectron spectroscopy and quartz crystal microbalance  
23 with dissipation monitoring),<sup>46</sup> 0.96 molecules/nm<sup>2</sup> at the air/water interface (surface  
24 tension)<sup>47</sup> and between 0.5 and 1.0 molecules/nm<sup>2</sup> in micelles respectively at the  
25 micelle/water and alkyl/sophorose interface (evaluated by SAXS).<sup>20</sup> The SL-IONP with a  
26 diameter of 4.6 nm purified by Amicon have a ligand density of 3.3 molecules/nm<sup>2</sup>, which  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 is within the range of plausible grafting densities taking both the density of grafting sites  
4  
5  
6 and steric blocking during grafting into account. The other systems display values of SL-  
7  
8  
9 NDA/nm<sup>2</sup> that are higher than the number of possible grafting sites on the IONP surface,  
10  
11  
12 which sets an absolute upper bound on the grafting density. Hence, the observed values  
13  
14  
15 above 5 molecules/nm<sup>2</sup> (Table 2) must be due to excess ligand that is not grafted to the  
16  
17  
18 IONP surface. The excess ligand could not be removed with Amicon filters and dialysis  
19  
20  
21  
22  
23 could also not reduce the organic content of the samples. It has been reported that  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

Figures 3B-C and Figures S6 and S7 show cryo-TEM images of 14.1 and 4.6 nm SL-IONP purified by membrane centrifugation. The 14.1 nm cores have the highest organic content according to TGA, while the 4.6 nm cores have an organic content compatible

1  
2  
3 with maximum grafting of SL-NDA to the IONP surface. In addition to the nicely dispersed  
4  
5  
6  
7 SL-IONP with high electron density contrast, large and elongated structures with lower  
8  
9  
10 contrast are present primarily in the 14.1 nm core sample; these strongly resemble the  
11  
12  
13  
14 filamentous structures formed by SL-NDA in water, depicted in Figure 3A.



30  
31 **Figure 3.** Cryo-TEM micrographs in H<sub>2</sub>O of A) SL-NDA, B) 14.1 nm SL-IONP and C) 4.6  
32  
33  
34 nm SL-IONP. The blue arrows indicate lamellar structures formed by excess ligand; the  
35  
36  
37 black dots are nanoparticles (see Figure S6 and S7 for enlarged pictures).

38  
39  
40  
41  
42  
43  
44  
45  
46 This feature suggests why SL-NDA could not be fully removed by dialysis or by  
47  
48  
49 membrane centrifugation: the cut-off pore size of the membranes is larger than a single  
50  
51  
52  
53 SL-NDA molecule, but smaller than their self-assembled phase. Dialysis should in

1  
2  
3 principle allow for removal of excess lipid from the sample, but in practice, self-  
4  
5  
6  
7 aggregating molecules with a low critical aggregation constant or very slow kinetics of  
8  
9  
10 desorption (low  $k_{off}$ ) will make dialysis very inefficient; this is apparently the case for  
11  
12  
13 dialysis of SL-NDA forming large and stable structures. An attempt to improve the dialysis  
14  
15  
16  
17 with salt (NaCl) by shifting the critical micelle concentration failed for this system since  
18  
19  
20  
21 SL-NDA micelles are insensitive to salt (*cf.* SANS data below). Interestingly, the small  
22  
23  
24 core sample (4.6 nm) had much less excess ligand after purification than the large core  
25  
26  
27  
28 sample. This could tentatively be explained by that for the larger cores a larger excess of  
29  
30  
31 SL-NDA to IONP surface area was used, which favors growth of more and larger micelles  
32  
33  
34 during grafting or during resuspension. The 4.6 nm SL-grafted IONP presumably had a  
35  
36  
37  
38 lower amount of excess SL-NDA in solution after grafting and consequently a negligible  
39  
40  
41  
42 excess of SL-NDA in the dispersion after purification. This interpretation of the purification  
43  
44  
45 and TGA data is supported by cryo-TEM (Figure 3C and Figure S7), in which many  
46  
47  
48  
49 stabilized nanoparticles are observed, but only a limited amount of SL-NDA. With the  
50  
51  
52  
53 difficulty to purify nanoparticles from SL-NDA micelles and filaments, one can try to  
54  
55  
56 minimize the excess of SL-NDA during grafting to suppress micelle formation. However,  
57  
58  
59  
60

1  
2  
3 this easily leads to inefficient grafting and sub-monolayer dispersant grafting density on  
4  
5  
6  
7 the particle surface. Grafting with large SL-NDA excess is therefore recommended for  
8  
9  
10 applications where excess micelles can be tolerated but particle colloidal stability is of  
11  
12  
13  
14 paramount importance.  
15  
16  
17  
18  
19  
20

21 **Characterization of the SL-NDA ligand shell with SANS and SAXS.** It is typically  
22  
23  
24 assumed that the high colloidal stability of coated nanoparticles is explained by the  
25  
26  
27 presence of a single layer of ligand; this argument may also hold for the SL-IONP  
28  
29  
30 presented here. However, most classical techniques, like DLS or TEM, on which this  
31  
32  
33  
34 assumption is based, are generally not providing *in situ* or detailed enough data to  
35  
36  
37  
38 quantitatively investigate the presence, structure and properties of the shell in support of  
39  
40  
41 this hypothesis. SAXS, which is sometimes used for this purpose, is mostly not suitable  
42  
43  
44  
45 for hybrid inorganic-organic nanoparticles, because the contrast between the solvent and  
46  
47  
48 the electron-rich inorganic core generally masks the signal of the shell resulting from the  
49  
50  
51 poor contrast between the solvent and the shell. The combined use of X-ray and neutron  
52  
53  
54  
55 scattering is the only method to probe the structural characteristics such as the thickness  
56  
57  
58  
59  
60



1  
2  
3 of the nanoparticle organic shell. In fact, neutrons, being scattered by the atom nuclei,  
4  
5  
6  
7 are less sensitive to atoms with high atomic number. We therefore combined SAXS and  
8  
9  
10 SANS as a reliable method to estimate the extension of the SL-NDA shell for SL-IONP  
11  
12  
13  
14 purified by Amicon filtration, that had a low excess of ligand in micelles.  
15  
16

17 SAXS was used to determine and confirm the size of the IONP cores. Under X-ray  
18  
19  
20 irradiation, the inorganic core of SL-IONP nanoparticles has a very high contrast ( $\rho_{solv} -$   
21  
22  
23  $\rho_c = -30.60 \times 10^{-6} \text{ \AA}^{-2}$ , Table 3) if compared to the shell-solvent ( $\rho_{solv} - \rho_s = -0.57 \times 10^{-6}$   
24  
25  
26  $\text{\AA}^{-2}$ , Table 3); for this reason, SAXS only provides structural information on the  
27  
28  
29  
30  
31 nanoparticle cores. Figure 4A (green circles) shows the SAXS profile for 4.6 nm SL-IONP.  
32  
33  
34  
35 The best fit using a core-shell sphere form factor can be obtained using an average  
36  
37  
38 nanoparticle core diameter of  $4.8 \pm 0.4$  nm and a null value for the shell thickness. This  
39  
40  
41  
42 is in very good agreement with the diameter obtained by TEM ( $4.6 \pm 0.3$  nm) within the  
43  
44  
45 experimental errors. The corresponding SANS pattern (Figure 4A, blue circles) is shifted  
46  
47  
48  
49 towards the low- $q$  region, which signifies sensitivity to the larger size resulting from the  
50  
51  
52  
53 much higher contrast of neutrons to the lipid shell.  
54  
55  
56  
57  
58  
59  
60


1  
2  
3  
4 The SANS pattern can be modeled using an imposed (from SAXS data) core diameter  
5  
6  
7 of  $d = 4.8 \pm 0.4$  nm and a shell thickness of  $t = 2.5 \pm 0.2$  nm obtained by fitting a core-  
8  
9  
10 shell model to the scattering data. This simple model assumes a uniform scattering length  
11  
12  
13 density throughout the shell, which is clearly a simplification, but it can be used to estimate  
14  
15  
16 the shell thickness by fitting the shift of the first minimum of the form factor. The calculated  
17  
18  
19 length of SL, considering the  $120^\circ$  angle due to the mono-unsaturation, can be estimated  
20  
21  
22 to 2.6 nm, where 1.6 nm are attributed to the fatty acid<sup>48</sup> and 1 nm to sophorose, in  
23  
24  
25 analogy to the size of maltose, a common disaccharide.<sup>49</sup> The size of NDA is estimated  
26  
27  
28 to about 1 nm.<sup>50</sup> Under these conditions, the maximum expected size for SL-NDA is about  
29  
30  
31 3.6 nm. The modeled thickness of  $t = 2.5 \pm 0.2$  nm is shorter than the maximum  
32  
33  
34 monolayer thickness and demonstrates that the shell of monodisperse SL-IONP is  
35  
36  
37 comprised of a single layer of SL-NDA of less than maximum density. From the fit, one  
38  
39  
40 can also evaluate an average shell scattering length density of  $\rho_s = 3.39 \times 10^{-6} \text{ 10}^{-6} \text{ \AA}^{-2}$ , a  
41  
42  
43 value which is reasonable for a hydrated (in  $D_2O$ ) organic lipid layer.<sup>51</sup> The lower density  
44  
45  
46 or slightly lower thickness that is observed can be explained in several ways. One can,  
47  
48  
49 e.g., consider that the shell could contain other smaller ligands than SL-NDA, such as  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 residual catalyst (COMU), oleic acid or unreacted NDA or SL. The combination of TGA,  
4  
5  
6  
7 FTIR and NMR data make this hypothesis unlikely. COMU, which was observed as  
8  
9  
10 residue in the SL-NDA batches used for grafting the NPs, has very low affinity for the iron  
11  
12  
13 oxide surface. All techniques employed show no evidence of residual OA, while <sup>1</sup>H NMR  
14  
15  
16 shows that the SL-NDA does not contain free NDA. A residual amount of unreacted SL  
17  
18  
19 (10-20 mol% with respect to SL-NDA) is present. The carboxyl endgroup of SL has high  
20  
21  
22 affinity to the IONP, but NDA functionalized ligands possess much higher affinity and  
23  
24  
25 outcompete carboxyl anchored ligands on the surface. This is demonstrated by FTIR  
26  
27  
28 showing the successful ligand replacement of OA by SL-NDA and previous studies of e.g.  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

A more plausible explanation for the thin shell is that the SL-NDA is grafted on a highly curved surface, which provides a rapidly increasing conical volume to the SL-NDA even at the highest grafting density.<sup>52</sup> This allows for a large tilt or bending of the molecules,

1  
2  
3 i.e. a lower effective shell thickness. The extended length of SL is calculated according  
4  
5  
6  
7 to the classical Tanford formula. However, SL is known to adopt a bent configuration,  
8  
9  
10 which yields an effectively thinner layer than theoretically calculated. For instance, XPS  
11  
12  
13 has shown that a single self-assembled monolayer of cysteamine-modified SL grafted  
14  
15  
16 onto flat gold has a thickness of only  $3.0 \pm 0.2$  nm,<sup>42</sup> while small-angle X-ray and neutron  
17  
18  
19 scattering measurements showed that the total radius of an acidic SL micelle is generally  
20  
21  
22 below 4 nm, i.e, approximately the size of a single SL molecule.<sup>53-54</sup> A layer grafted on a  
23  
24  
25 highly curved NP would be expected to yield a thickness in between these estimates.  
26  
27  
28  
29  
30

31 Finally, one should not exclude that the simplification of assuming a uniform scattering  
32  
33  
34 length density, which could be invalidated by the conical ligand volume and the highly  
35  
36  
37 hydrated headgroup, would also lead to a fit predicting an effectively thinner shell.  
38  
39  
40  
41 Whichever the dominant of the two latter explanations, the SAXS/SANS data demonstrate  
42  
43  
44  
45 a single thin SL-NDA layer serving as the stabilizing shell on the IONP.  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 4.** A) SANS (blue) and SAXS (green) profiles for 4.6 nm SL-IONP in D<sub>2</sub>O. The red lines show the fit obtained from a core-shell sphere model. The best fit for SAXS was obtained using a core diameter of 4.8 nm and a null value for the shell. B) Comparison of the SANS data of 4.6 nm (blue) and 3.1 nm SL-IONP (grey). As expected, the profile for smaller SL-IONP is shifted to larger  $q$ . The red lines show the fit obtained with a homogeneous core-shell model.

Similar results are obtained for the smaller 3.1 nm SL-IONP (Figure 4B). The SANS pattern can be modelled with a fixed (from SAXS data) core diameter,  $d = 3.0 \pm 0.2$  nm and a fitted shell thickness of  $t = 2.2 \pm 0.2$  nm. These data are summarized in Table 3,

which also contains the solvent-core and solvent-shell scattering length density contrasts fitted from the SANS data:  $\rho_{solv} - \rho_c = -0.57 \times 10^{-6} \text{ \AA}^{-2}$  while  $\rho_{solv} - \rho_s$  is in the order of  $3.0 \times 10^{-6} \text{ \AA}^{-2}$ . This demonstrates that the shell has higher contrast than the iron oxide core, and therefore dominates the scattering signal of the core-shell particle. The absolute value of the shell scattering length density for 3.1 nm SL-IONP is  $\rho_s = 3.45 \times 10^{-6} \text{ \AA}^{-2}$  and in good agreement with what is found for the 4.6 nm core SL-IONP.


**Table 3.** Structural parameters for the 3.1 nm and 4.6 nm SL-IONP obtained by combining TEM, SAXS and SANS analyses.

| Sample            | Technique | Core diameter<br>$d$ (nm) | Shell Thickness<br>$t$ (nm) | $\rho_{solv} - \rho_c$<br>( $\times 10^{-6} \text{ \AA}^{-2}$ ) | $\rho_{solv} - \rho_s$<br>( $\times 10^{-6} \text{ \AA}^{-2}$ ) |
|-------------------|-----------|---------------------------|-----------------------------|---|---|
| 3.1 nm<br>SL-IONP | TEM       | $3.1 \pm 0.2$             | -                           | -   | -   |
|                   | SAXS      | $3.0 \pm 0.4$             | -                           | -30.60  | < -1.00   |
|                   | SANS      | $3.0 \pm 0.4$             | $2.5 \pm 0.2$               | -0.57   | 2.63  |
| 4.6 nm<br>SL-IONP | TEM       | $4.6 \pm 0.2$             | -                           | -   | -   |
|                   | SAXS      | $4.8 \pm 0.4$             | -                           | -30.60  | < -1.00   |
|                   | SANS      | $4.8 \pm 0.4$             | $2.2 \pm 0.2$               | -0.57   | 3.00  |

1  
2  
3  
4  
5  
6  
7  
8  
9  
10 The scattering curve of the 14.1 nm SL-IONP sample was radically different to those of  
11  
12 the dispersions of the two smaller SL-grafted IONP and is shown in Figure 5. The typical  
13  
14 SANS spectrum for 14.1 nm SL-IONP in D<sub>2</sub>O (blue filled circles) is relatively featureless  
15  
16  
17 in D<sub>2</sub>O, but it shows strong scattering with a characteristic slope in the low- $q$  region that  
18  
19  
20 is not present in the SANS spectra of the smaller SL-grafted IONP. This additional feature  
21  
22  
23 can be explained by comparing the data to the SANS spectrum of the pure SL-NDA ligand  
24  
25  
26 solution (Figure 5, grey filled circles), which nicely matches the spectrum of the 14.1 nm  
27  
28  
29 SL-IONP sample. Thus, in good agreement with the TGA data presented in Figure S4  
30  
31  
32 and Table 2, the SANS signal of the 14.1 nm SL-IONP dispersion is dominated by SL-  
33  
34  
35 NDA in the form of filamentous structures instead of the core-shell particles. The higher  
36  
37  
38 contrast of SL-NDA to D<sub>2</sub>O than of iron oxide to D<sub>2</sub>O further contributes to the dominance  
39  
40  
41 of scattering from the SL-NDA micelles. These micelles were also prevalent in cryo-TEM  
42  
43  
44 images of the 14.1 nm SL-IONP sample (see Figure 3B). Nonetheless, SL-NDA is soluble  
45  
46  
47 in perdeuterated methanol, as shown by the corresponding poor SANS signal (grey empty  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 circles) in Figure 5 5. As expected, the SANS pattern of 14.1 nm SL-IONP (blue empty  
5  
6  
7 circles) in MeOD-d4 loses the SL-NDA scattering profile and it rather presents the typical  
8  
9  
10 feature of spherical objects. A shell-free 14.1 nm diameter IONP nanoparticle would be  
11  
12  
13  
14 expected to have the first minimum of the form factor around  $q = 0.4 \text{ nm}^{-1}$ , whereas the  
15  
16  
17  
18 minimum of the oscillation of the form factor measured for the 14.1 nm SL-IONP falls  
19  
20  
21 between  $0.2 \text{ nm}^{-1} < q < 0.3 \text{ nm}^{-1}$ , suggesting a spherical object sized between 20 and 30  
22  
23  
24 nm. This is largely in agreement to what would be expected for a 14.1 nm iron oxide core,  
25  
26  
27  
28 stabilized by a single SL-NDA layer even if the conditions of analysis (excess of SL-NDA,  
29  
30  
31 methanol) and likely presence of aggregates do not allow the quantification of the  
32  
33  
34  
35 thickness of the SL-NDA layer.  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





**Figure 5.** SANS data recorded for 14.1 nm SL-IONP in  $\text{D}_2\text{O}$  (blue filled circles) and MeOD-d4 (blue empty circles) and the pure ligand SL-NDA in  $\text{D}_2\text{O}$  (grey filled circles) and MeOD-d4 (grey empty circles).

**Colloidal stability and long-term stability.** Removal of all monomeric free SL-NDA, is a good test of the colloidal stability of SL-NDA-grafted IONP. However, a biological environment is much more challenging for IONP colloidal stability, due to the higher concentration of biological colloids, displaying a larger variety of attractive interactions and leading to nanoparticle aggregation.<sup>5</sup> Thus, colloidal stability of nanoparticles meant

1  
2  
3 to perform functions in biotechnological or medical applications should be tested under  
4  
5  
6  
7 conditions where they are exposed to full physiological ionic strength as well as to  
8  
9  
10 concentrations of protein similar to those that could be encountered during application.

11  
12  
13 Therefore, we suspended the SL-IONP in 10 % fetal calf serum (FCS), which has a lower  
14  
15  
16 concentration than full serum, but at which the colloidal stability can be monitored by DLS.

17  
18  
19  
20  
21 10 % serum also corresponds to the typical additive to cell culture media. We performed  
22  
23  
24 the measurements while heating from 20 °C to 70 °C and back. These conditions are  
25  
26  
27 known to weaken the hydration of the nanoparticle shell<sup>55</sup> and thereby reduce the colloidal  
28  
29  
30 stability and decrease the ability to suppress adsorption of serum protein. Adsorption of  
31  
32  
33 denatured proteins leads to irreversible aggregation and precipitation of insufficiently  
34  
35  
36 stabilized nanoparticles<sup>56</sup>. Figure 6 shows the evolution of the volume weighted  
37  
38  
39 hydrodynamic diameter  $D_H$  of 4.6 nm SL-IONP in water with 10 % FCS with temperature.  
40  
41  
42  
43  
44


45 Volume weighed  $D_H$  of 4.6 nm SL-IONP in water is shown in Figure S8A. The  
46  
47  
48 hydrodynamic diameter of 4.6 nm SL-IONP was measured to be around 12 nm, which  
49  
50  
51 was stable after more than 1.5 years in storage. The SL-IONP with 3.1 nm and 14.1 nm  
52  
53  
54 core sizes appeared equally stable in dispersion over the same time period. However, the  
55  
56  
57  
58  
59  
60

1  
2  
3 stability could not be quantitatively confirmed by the hydrodynamic diameter, as there  
4  
5  
6  
7 were excess SL-NDA in these samples. All investigated SL-IONP have small diameters  
8  
9  
10 in the superparamagnetic range and they are stabilized predominantly by steric and  
11  
12  
13 hydration forces from the hydrophilic headgroup region of the sophorolipid. It is  
14  
15  
16  
17 advantageous for many applications to have a thin stabilizing shell of this kind to reduce  
18  
19  
20  
21 the overall hydrodynamic size. However, we note that the strength of the long-range  
22  
23  
24 attractive van der Waals forces increases if the inorganic nanoparticle core is made  
25  
26  
27 larger. It is likely that there is a maximum core size for which an SL-NDA shell can provide  
28  
29  
30  
31 sufficient stabilization against aggregation by dipolar interactions.  
32  
33

34  
35 The hydrodynamic diameter of the 4.6 nm SL-IONP is in reasonable agreement with  
36  
37  
38 the size of the core-shell nanoparticle determined by SANS, ~9.2 nm, which might  
39  
40  
41 underestimate the steric or hydrodynamic size due to the fitting of a homogeneous shell.  
42  
43  
44  
45 The DLS result is also in good agreement with a theoretical size of a core-shell IONP  
46  
47  
48 calculated from the diameter of the core measured by TEM (4.6 nm) and the length of a  
49  
50  
51  
52 SL-NDA molecule (3 nm), which implies a total steric diameter of 10.6 nm diameter. Thus,  
53  
54  
55  
56 both DLS and SANS data strongly suggest a monolayer of SL-NDA ligands on the NP  
57  
58  
59  
60

1  
2  
3 surface. The size distribution measured for the monodisperse iron oxide nanoparticles  
4  
5  
6  
7 grafted with SL-NDA is narrower and with a smaller  $D_H$  than the SL-coated iron oxide  
8  
9  
10 nanoparticles reported in our earlier work.<sup>26</sup> This is attributed to the novel synthesis  
11  
12  
13  
14 protocol with improved ligand and anchor chemistry for grafting to monodisperse iron  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

surface. The size distribution measured for the monodisperse iron oxide nanoparticles grafted with SL-NDA is narrower and with a smaller  $D_H$  than the SL-coated iron oxide nanoparticles reported in our earlier work.<sup>26</sup> This is attributed to the novel synthesis protocol with improved ligand and anchor chemistry for grafting to monodisperse iron oxide core particles. Volume weighted  $D_H$  size distributions of 10 % FCS in Milli-Q without nanoparticles measured at 20 °C and 70 °C are shown in Figure S8B. The size of serum proteins was measured to be ~5 nm at 20 °C. A size shift to 8 nm was observed at elevated temperatures.




48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Figure 6.** Volume weighted hydrodynamic diameters  $D_H$  of 4.6 nm SL-IONP dispersed in water with 10 % FCS heated from A) 20 °C to 70 °C and B) cooled from 70 °C to 20 °C with 3 minutes equilibration time at each temperature.

1  
2  
3  
4  
5  
6  
7  
8 When heating up the SL-IONP in FCS, we observed a size distribution with the main  
9  
10  
11 peak corresponding to the abundant serum albumin, with a tail towards larger sizes  
12  
13  
14 contributed by the SL-IONP. Upon heating, the fraction of small objects (serum albumin)  
15  
16  
17 in the size distribution decreased and the volume fraction of larger objects (nanoparticles)  
18  
19  
20 increased. This results from partial denaturation and aggregation of serum proteins. This  
21  
22  
23 trend becomes even more obvious in Figure 6B where a temperature of 70 °C was held  
24  
25  
26 for 8 minutes to allow for more equilibration of the sample. Here, the apparent volume  
27  
28  
29 fraction of nanoparticles is even larger, which could be due to precipitation of serum  
30  
31  
32 protein. Importantly, no aggregation and precipitation of SL-IONP was observed at any  
33  
34  
35 temperature, with or without exposure to denatured serum protein. This can also be  
36  
37  
38 observed from the intensity weighted size distributions for the same temperature cycling  
39  
40  
41 experiment (Figure S11). Figure S9 shows a photograph of SL-IONP after temperature  
42  
43  
44 cycling. Aggregation of SL-IONP could not be induced by heating the samples in FCS at  
45  
46  
47 70 °C for 3 h (Figure S10). Similar to the observations during temperature cycling, only a  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 small shift in size is observed after heating for 3 h and a very small peak in the intensity  
4  
5  
6  
7 weighted  $D_H$  appears at large sizes, indicating the aggregation of the protein that  
8  
9  
10 precipitated after 3 h heating (Figure S12). These data, showing the excellent stability of  
11  
12  
13 SL-IONP with temperature, can be explained by the small influence that temperature has  
14  
15  
16  
17 on the dehydration of the carbohydrate moiety of sugar-based capping agents. Sugar-  
18  
19  
20 based dispersants are both hydrogen-bond donors and acceptors, which allows for a bulk  
21  
22  
23 water-like hydrogen-bonding network and thereby low sensitivity to dehydration upon  
24  
25  
26  
27 increasing temperature.  
28  
29  
30

31 The excellent colloidal stability of the SL-IONP nanoparticles is further demonstrated by  
32  
33  
34 additional experiments performed in the presence of 1 M NaCl in  $D_2O$ . The high ionic  
35  
36  
37 strength of 1 M NaCl was chosen for the ability of the NaCl ions to screen and reduce  
38  
39  
40 double layer repulsion, thereby increasing the propensity of nanoparticles to aggregate,  
41  
42  
43 as well as the ability of the mild kosmotropes to reduce hydration and thereby decrease  
44  
45  
46 stabilization due to steric and hydration forces. Figure 7 presents the typical SANS  
47  
48  
49 spectra for the 3.1 nm and 4.6 nm SL-IONP in 1 M NaCl  $D_2O$  in comparison with SL-IONP  
50  
51  
52  
53  
54  
55  
56 in pure  $D_2O$ .  
57  
58  
59  
60



**Figure 7.** SANS data recorded for 3.1 nm and 4.6 nm SL-IONP in  $\text{D}_2\text{O}$  (red and grey filled circles respectively) and in 1 M NaCl (dissolved in  $\text{D}_2\text{O}$ ) (red and grey empty circles respectively).

The data show that the SANS profiles of neither sample change when the ionic strength of the solvent is increased. The absence of change is true in both the mid/high- $q$  region characteristic of the core-shell structure and in the low- $q$  region characteristic of aggregation. This indicates that the SL-NDA shell has neither been removed upon salt addition, nor has its structure been modified. This contrasts to previous findings for

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

sophorolipid coated nanoparticles, where aggregation was promoted by the addition of salt.<sup>26</sup> The improved stability of our novel SL-IONP can be attributed to the NDA anchor chemistry that irreversibly grafts the SL coating densely to the cores. Furthermore, the SANS profiles do not show any sign of particle aggregation, since a structure factor corresponding to particle aggregation would appear in the low  $q$ -range. There is also no optically visible increase in scattering nor does precipitation take place, which supports the SANS observation of excellent colloidal stability. This is in full agreement with the DLS data that showed retained size and no aggregation and precipitation (*cf.* Figure 6). The SANS measurements also show that micelles of excess ligand in the 3.1 nm SL-IONP sample were not altered by that addition of salt (no change in the slope at low  $q$ ), which explains why dialysis at high ionic strength could not remove the excess ligand.


***In-vitro* cellular uptake and cytotoxicity of SL-IONP.** To prove the applicability of SL-IONP in the biomedical field, we conducted cellular uptake and cytotoxicity tests on two different cell lines: U937 monocytes which are part of the reticuloendothelial system and



1  
2  
3 responsible for clearance of pathogens and foreign bodies from the blood and MCF7, a  
4  
5  
6  
7 human breast cancer cell line.  
8  
9

10 Differentiated monocytes, macrophages, are the cells in the body that are most exposed  
11  
12  
13  
14 to toxins and foreign bodies. The response of these cells to exposure of SL-IONP is thus  
15  
16  
17 of highest relevance. If they detect and scavenge nanoparticles, the nanoparticles will be  
18  
19  
20  
21 of limited use in applications that require circulation and/or targeting. It is, to the best of  
22  
23  
24 our knowledge, the first time that cellular uptake and toxicity are studied for sophorolipid  
25  
26  
27 coated core-shell nanoparticles. Figure 8 shows the results of the cellular uptake and  
28  
29  
30 cytotoxicity tests for 4.6 nm SL-IONP with U937 and MCF7 cells. SL-IONP show very low  
31  
32  
33 non-specific uptake by both monocytes and cancer cells. A slight trend to higher uptake  
34  
35  
36 of breast cancer cells over the phagocytic monocytes could not be statistically verified.  
37  
38  
39  
40  
41 The low uptake is in the same order as previously shown for stealth poly(ethylene glycol)-  
42  
43  
44 grafted IONP<sup>9</sup> and can be traced back to the good colloidal stability of the core-shell SL-  
45  
46  
47 IONP and their resistance against aggregation in presence of proteins and salts (*cf.*  
48  
49  
50  
51  
52 Figure 6 and 7).  
53  
54  
55  
56  
57  
58  
59  
60

Both sphorolipids and iron oxide nanoparticles have individually shown negligible toxicity at relevant concentrations to various cell lines.<sup>57-58</sup> Figure 8B shows that also SL-grafted 4.6 nm IONP do not affect the viability of the two tested cell lines. The results suggest an excellent biocompatibility of the SL-IONP.



**Figure 8.** A) Cellular uptake of 4.6 nm SL-IONP for human monocytes (U937) and human breast cancer cells (MCF7). Negligible uptake was observed with a tendency towards increased uptake in cancer cell lines, but without statistical significance ( $p > 0.05$  ANOVA 1-way) within the study. B) Cytotoxicity tests for 4.6 nm SL-IONP with human monocytes (U937) and human breast cancer cells (MCF7). The viability was unchanged for both cell lines.

1  
2  
3  
4  
5  
6 **Design principles for using SL-NDA to stabilize IONP for applications.** In summary, a  
7  
8  
9 range of challenging conditions for colloidal stability relevant for applications were tested;  
10  
11  
12 all results were consistent with excellent stability of the grafted SL-NDA shell translating  
13  
14  
15 to equally excellent colloidal stability. The low size dispersity, high grafting density and  
16  
17  
18 colloidal stability of the SL-IONP system developed here are comparable to those of  
19  
20  
21 synthetic glyconanoparticles<sup>12, 16-17, 59-60</sup> rather than sophorolipid-capped nanoparticles.<sup>23-</sup>  
22  
23  
24  
25  
26  
27 <sup>26</sup> Our results demonstrate that the densely grafted SL-NDA shell provides a stable  
28  
29  
30 repulsive potential preventing both mutual aggregation and protein adsorption under  
31  
32  
33 highly challenging conditions (1 M NaCl, 70 °C with and without FCS). The colloidal  
34  
35  
36 stability is not adversely affected by temperature and kosmotrope salts that often have a  
37  
38  
39 destabilizing effect on polymer coated-core-shell nanoparticles. This is reached by the  
40  
41  
42 irreversible grafting of the SL ligand to the core in contrast to pure self-assembly and/or  
43  
44  
45 complexation. The expected main contribution to the repulsive interaction of the shell is  
46  
47  
48 the high and stable hydration of the lipid head-groups that is apparently strong enough to  
49  
50  
51 withstand weakening in the coordination of associated water under relevant challenging  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 environmental conditions. This fact is confirmed by the literature on the micellization  
4  
5  
6  
7 properties of sugar-based amphiphiles: the strength between the hydrogen bonding  
8  
9  
10 between the hydroxyl groups of the sugar unit and water is stronger than between  
11  
12  
13  
14 ethylene oxide and water.<sup>61</sup>  
15  
16

17 It is worth noting that stabilization through a grafted lipid is fundamentally different to  
18  
19  
20 the more commonly applied approach of a high- $M_w$  flexible polymer; the low thickness  
21  
22  
23 added by a lipid monolayer and its insignificant molecular flexibility makes it possible to  
24  
25  
26  
27 design such shells much more compact and structurally precise than using solvated  
28  
29  
30  
31 polymer. At the same time, it is impressive that equally high colloidal stability, as  
32  
33  
34 demonstrated here, can be obtained. The hydrophobic spacer part of the lipid shell is  
35  
36  
37  
38 important to reduce core-core van-der-Waals attraction and likely cannot be made too  
39  
40  
41 thin without compromising colloidal stability. However, with a hydrophobic interior of the  
42  
43  
44 shell, a prerequisite for stability in biofluids is that the lipid shell (the lipid headgroup  
45  
46  
47 region) is dense enough to prevent hydrophobic molecules, such as protein denatured by  
48  
49  
50  
51 temperature, to adsorb to shell defects exposing the alkyl part of the lipids. We achieved  
52  
53  
54  
55 this by the stable NDA-coupling and efficient ligand exchange protocol used to graft the  
56  
57  
58  
59  
60

1  
2  
3 SL-NDA shell. As expected, in the absence of aggregates, the SL-IONP showed only  
4  
5  
6  
7 weak interaction with cells *in-vitro* with negligible uptake and no resulting cytotoxicity, thus  
8  
9  
10 making these systems promising candidates for the development of IONP-based  
11  
12  
13 biomedical applications. These, so-called stealth, nanoparticles can be further  
14  
15  
16  
17 functionalized or make use of specific interactions of the exposed saccharide motif to add  
18  
19  
20 targeting capability, for which structural and colloidal stability, as well as suppression of  
21  
22  
23 non-specific biomolecular interactions, is a prerequisite.  
24  
25  
26  
27  
28  
29  
30

## 31 Conclusion

32  
33  
34 We have synthesized monodisperse, biocompatible, sophorolipid-grafted core-shell  
35  
36  
37 iron oxide nanoparticles with excellent colloidal stability in demanding application  
38  
39  
40 environments mimicking the conditions of biological fluids. As-synthesized, oleic acid-  
41  
42  
43 coated IONP with precisely tunable sizes and narrow size distributions were successfully  
44  
45  
46  
47 grafted with a nitrodopamide-modified sophorolipid ligand by replacement of the oleic  
48  
49  
50  
51 acid. Analysis of TGA and cryo-TEM highlighted the challenge of removing excess ligand  
52  
53  
54  
55 as sophorolipid forms very stable aggregates of similar size as the grafted nanoparticles  
56  
57  
58  
59  
60

1  
2  
3 and with the same physico-chemical characteristics. Cryo-TEM revealed the coexistence  
4  
5  
6  
7 of individual, monodisperse, SL-grafted IONP with large and stable SL-NDA aggregates  
8  
9  
10 formed by excess ligand that could not be completely removed by excessive purification.  
11  
12  
13  
14 However, also close to pure SL-grafted IONP product was obtained for 4.6 nm IONP  
15  
16  
17 cores. The core-shell structure of SL-IONP was analyzed by SAXS and SANS. The  
18  
19  
20 resulting data were successfully fitted with a core-shell model. SANS revealed the  
21  
22  
23  
24 thickness of the shell, which was found to be in the order of 2.5 nm, in good agreement  
25  
26  
27  
28 with a shell composed of a monolayer of SL-NDA grafted to a highly curved surface.  
29  
30

31 The stable, grafted core-shell architecture presenting the equivalent of a dense  
32  
33  
34 sphorolipid membrane at the nanoparticle surface was shown to translate into excellent  
35  
36  
37  
38 colloidal stability under demanding conditions such as in dense protein dispersions  
39  
40  
41 (serum) at high temperature and at high ionic strength, as shown by DLS and SANS. The  
42  
43  
44  
45 resulting colloidally stable and biocompatible SL-IONP are promising materials in the  
46  
47  
48  
49 biomedical field through their combination of IONP imaging and therapeutic properties  
50  
51  
52 with natural presentation of functional glycosylation, whereas carbohydrate-rich  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 nanoparticles can display unique targeting ability towards lectin-rich biological  
4  
5  
6  
7 membranes, including tumor cells and pathogenic bacteria.  
8  
9  
10  
11  
12  
13  
14

## 15 ASSOCIATED CONTENT

16  
17  
18

19 **Supporting Information.** Additional information on Materials. Control over iron oxide core  
20  
21  
22 size by the precursor to surfactant ratio. Detailed synthetic protocols. NMR, IR, TGA,  
23  
24  
25  
26 TEM, cryo-TEM and DLS data for SL-NDA and SL-IONP. Photos of colloidal suspensions.  
27  
28  
29  
30 Additional SAXS and SANS data with fits.  
31  
32  
33

## 34 AUTHOR INFORMATION

35  
36  
37

### 38 Corresponding Authors

39  
40  
41

42 \*Erik Reimhult: [erik.reimhult@boku.ac.at](mailto:erik.reimhult@boku.ac.at); Niki Baccile: [niki.baccile@upmc.fr](mailto:niki.baccile@upmc.fr).  
43  
44  
45

### 46 Author Contributions

47  
48  
49

50 AL, ER and NB planned the work. AL and NB performed most of the experiments. AL, ER  
51  
52  
53 and NB wrote the manuscript. All authors contributed to and reviewed the manuscript.  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 The manuscript was written through contributions of all authors. All authors have given  
5  
6  
7 approval to the final version of the manuscript.  
8  
9

## 10 11 **Funding Sources** 12

13  
14  
15 This work received financial support by the Institut Laue-Langevin (ILL), Grenoble,  
16  
17  
18 France, under the experiment number 9-12-481 (D33, D16 beamlines), and by the  
19  
20  
21 European Synchrotron Radiation Facility (ESRF), Grenoble, France, under the  
22  
23  
24  
25 experiment number SC-4419. The research presented in that paper was funded by the  
26  
27  
28  
29 Austrian Science Fund (FWF) project I 3064 and by the European Research Council  
30  
31  
32 under the European Union's Seventh Framework Program (FP/2007-2013)/ERC Grant  
33  
34  
35  
36 Agreement No. 310034.  
37  
38  
39

## 40 **ACKNOWLEDGMENT** 41

42  
43  
44  
45 This work benefited from the use of the SasView application, originally developed under  
46  
47  
48 NSF award DMR-0520547. SasView contains code developed with funding from the  
49  
50  
51 European Union's Horizon 2020 research and innovation programme under the  
52  
53  
54  
55 SINE2020 project, grant agreement No 654000. We thank the Lawrence Berkeley  
56  
57  
58  
59  
60



1  
2  
3  
4 National Laboratory for access to TEM; work at the Molecular Foundry was supported by  
5  
6  
7 the Office of Science, Office of Basic Energy Sciences, of the U.S. Department of Energy  
8  
9  
10 under Contract No. DE-AC02-05CH11231. We thank Prof. Dieter Baurecht for access to  
11  
12  
13  
14 FTIR. We acknowledge the VIBT Extremophile Center for access to TGA.  
15  
16  
17  
18  
19  
20

## 21 ABBREVIATIONS

22  
23 IONP, iron oxide nanoparticles; OA, oleic acid; Oct<sub>2</sub>O, dioctylether; SL, sophorolipids;  
24  
25  
26  
27 NDA, nitrodopamine/nitrodopamide; SL-NDA, sophorolipid-nitrodopamide; SL-IONP,  
28  
29  
30 sophorolipid-nitrodopamide-grafted iron oxide nanoparticles; PEG, poly(ethylene glycol);  
31  
32  
33  
34 PBS, Phosphate buffered saline; FCS, fetal calf serum; HR, high-resolution; LR, low-  
35  
36  
37 resolution; TEM, transmission electron microscope/microscopy; TGA, thermogravimetric  
38  
39  
40  
41 analysis; DLS, dynamic light scattering; NMR, nuclear magnetic resonance; ATR-FTIR,  
42  
43  
44 attenuated total reflection – Fourier transform infra-red; SAXS, small angle x-ray  
45  
46  
47 scattering; SANS, small angle neutron scattering; SLD, scattering length density; MWCO,  
48  
49  
50  
51 molecular weight cut-off; TOC, total organic content  
52  
53  
54  
55  
56  
57  
58  
59  
60

## REFERENCES

1. Hong, R. Y.; Feng, B.; Chen, L. L.; Liu, G. H.; Li, H. Z.; Zheng, Y.; Wei, D. G., Synthesis, Characterization and MRI Application of Dextran-Coated Fe<sub>3</sub>O<sub>4</sub> Magnetic Nanoparticles. *Biochem. Eng. J.* 2008, 42, 290-300.
2. Lacava, L. M.; Lacava, Z. G. M.; Da Silva, M. F.; Silva, O.; Chaves, S. B.; Azevedo, R. B.; Pelegrini, F.; Gansau, C.; Buske, N.; Sabolovic, D.; Morais, P. C., Magnetic Resonance of a Dextran-Coated Magnetic Fluid Intravenously Administered in Mice. *Biophys. J.* 2001, 80, 2483-2486.
3. Tassa, C.; Shaw, S. Y.; Weissleder, R., Dextran-Coated Iron Oxide Nanoparticles: A Versatile Platform for Targeted Molecular Imaging, Molecular Diagnostics, and Therapy. *Acc. Chem. Res.* 2011, 44, 842-852.
4. Boni, A.; Bardi, G.; Bertero, A.; Cappello, V.; Emdin, M.; Flori, A.; Gemmi, M.; Innocenti, C.; Menichetti, L.; Sangregorio, C.; Villa, S.; Piazza, V., Design and Optimization of Lipid-Modified Poly(Amidoamine) Dendrimer Coated Iron Oxide Nanoparticles as Probes for Biomedical Applications. *Nanoscale* 2015, 7, 7307-7317.
5. Amstad, E.; Textor, M.; Reimhult, E., Stabilization and Functionalization of Iron Oxide Nanoparticles for Biomedical Applications. *Nanoscale* 2011, 3, 2819-2843.
6. Frey, N. A.; Peng, S.; Cheng, K.; Sun, S., Magnetic Nanoparticles: Synthesis, Functionalization, and Applications in Bioimaging and Magnetic Energy Storage. *Chem. Soc. Rev.* 2009, 38, 2532-2542.
7. Park, J.; Joo, J.; Kwon, S. G.; Jang, Y.; Hyeon, T., Synthesis of Monodisperse Spherical Nanocrystals. *Angew. Chem. Int. Ed.* 2007, 46, 4630-4660.
8. Lassenberger, A.; Bixner, O.; Gruenewald, T.; Lichtenegger, H.; Zirbs, R.; Reimhult, E., Evaluation of High-Yield Purification Methods on Monodisperse Peg-Grafted Iron Oxide Nanoparticles. *Langmuir* 2016, 32, 4259-4269.
9. Lassenberger, A.; Scheberl, A.; Stadlbauer, A.; Stiglbauer, A.; Helbich, T.; Reimhult, E., Individually Stabilized, Superparamagnetic Nanoparticles with Controlled Shell and Size Leading to Exceptional Stealth Properties and High Relaxivities. *ACS Appl. Mater. Interfaces* 2017, 9, 3343-3353.

10. Yang, Q.; Lai, S. K., Anti-PEG Immunity: Emergence, Characteristics, and Unaddressed Questions. Wiley interdisciplinary reviews. Nanomed. Nanobiotechnol. 2015, 7, 655-677.
11. Bernardi, A.; Jimenez-Barbero, J.; Casnati, A.; De Castro, C.; Darbre, T.; Fieschi, F.; Finne, J.; Funken, H.; Jaeger, K.-E.; Lahmann, M.; Lindhorst, T. K.; Marradi, M.; Messner, P.; Molinaro, A.; Murphy, P. V.; Nativi, C.; Oscarson, S.; Penades, S.; Peri, F.; Pieters, R. J.; Renaudet, O.; Reymond, J.-L.; Richichi, B.; Rojo, J.; Sansone, F.; Schaffer, C.; Turnbull, W. B.; Velasco-Torrijos, T.; Vidal, S.; Vincent, S.; Wennekes, T.; Zuilhof, H.; Imberty, A., Multivalent Glycoconjugates as Anti-Pathogenic Agents. Chem. Soc. Rev. 2013, 42, 4709-4727.
12. Marradi, M.; Chiodo, F.; Garcia, I.; Penades, S., Glyconanoparticles as Multifunctional and Multimodal Carbohydrate Systems. Chem. Soc. Rev. 2013, 42, 4728-4745.
13. Lee, Y. C.; Lee, R. T., Carbohydrate-Protein Interactions: Basis of Glycobiology. Acc. Chem. Res. 1995, 28, 321-327.
14. Lis, H.; Sharon, N., Lectins: Carbohydrate-Specific Proteins That Mediate Cellular Recognition. Chem. Rev. 1998, 98, 637-674.
15. Cecioni, S.; Imberty, A.; Vidal, S., Glycomimetics Versus Multivalent Glycoconjugates for the Design of High Affinity Lectin Ligands. Chem. Rev. 2015, 115, 525-561.
16. El-Boubbou, K.; Zhu, D. C.; Vasileiou, C.; Borhan, B.; Prospero, D.; Li, W.; Huang, X., Magnetic Glyco-Nanoparticles: A Tool to Detect, Differentiate, and Unlock the Glyco-Codes of Cancer Via Magnetic Resonance Imaging. J. Am. Chem. Soc. 2010, 132, 4490-4499.
17. Gallo, J.; Garcia, I.; Padro, D.; Arnaiz, B.; Penades, S., Water-Soluble Magnetic Glyconanoparticles Based on Metal-Doped Ferrites Coated with Gold: Synthesis and Characterization. J. Mater. Chem. B 2010, 20, 10010-10020.
18. Dumur, F.; Guerlin, A.; Dumas, E.; Bertin, D.; Gigmes, D.; Mayer, C. R., Controlled Spontaneous Generation of Gold Nanoparticles Assisted by Dual Reducing and Capping Agents. Gold Bulletin 2011, 44, 119-137.

19. Duan, H.; Wang, D.; Li, Y., Green Chemistry for Nanoparticle Synthesis. *Chem. Soc. Rev.* 2015, 44, 5778-5792.
20. Manet, S.; Cuvier, A.-S.; Valotteau, C.; Fadda, G. C.; Perez, J.; Karakas, E.; Abel, S.; Baccile, N., Structure of Bolaamphiphile Sophorolipid Micelles Characterized with SAXS, SANS, and MD Simulations. *J. Phys. Chem. B* 2015, 119, 13113-13133.
21. Chen, J.; Song, X.; Zhang, H.; Qu, Y., Production, Structure Elucidation and Anticancer Properties of Sophorolipid from *Wickerhamiella Domercqiae*. *Enzyme Microb. Technol.* 2006, 39, 501-506.
22. Díaz De Rienzo, M. A.; Banat, I. M.; Dolman, B.; Winterburn, J.; Martin, P. J., Sophorolipid Biosurfactants: Possible Uses as Antibacterial and Antibiofilm Agent. *New Biotechnol.* 2015, 32, 720-726.
23. Kasture, M.; Singh, S.; Patel, P.; Joy, P. A.; Prabhune, A. A.; Ramana, C. V.; Prasad, B. L. V., Multiutility Sophorolipids as Nanoparticle Capping Agents: Synthesis of Stable and Water Dispersible Co Nanoparticles. *Langmuir* 2007, 23, 11409-11412.
24. Singh, S.; Patel, P.; Jaiswal, S.; Prabhune, A. A.; Ramana, C. V.; Prasad, B. L. V., A Direct Method for the Preparation of Glycolipid-Metal Nanoparticle Conjugates: Sophorolipids as Reducing and Capping Agents for the Synthesis of Water Re-Dispersible Silver Nanoparticles and Their Antibacterial Activity. *New J. Chem.* 2009, 33, 646-652.
25. Kumar, D. V. R.; Kasture, M.; Prabhune, A. A.; Ramana, C. V.; Prasad, B. L. V.; Kulkarni, A. A., Continuous Flow Synthesis of Functionalized Silver Nanoparticles Using Bifunctional Biosurfactants. *Green Chem.* 2010, 12, 609-615.
26. Baccile, N.; Noiville, R.; Stievano, L.; Bogaert, I. V., Sophorolipids-Functionalized Iron Oxide Nanoparticles. *Phys. Chem. Chem. Phys.* 2013, 15, 1606-1620.
27. Amstad, E.; Gehring, A. U.; Fischer, H.; Nagaiyanallur, V. V.; Hahner, G.; Textor, M.; Reimhult, E., Influence of Electronegative Substituents on the Binding Affinity of Catechol-Derived Anchors to Fe<sub>3</sub>O<sub>4</sub> Nanoparticles. *J. Phys. Chem. C* 2011, 115, 683-691.
28. Amstad, E.; Gillich, T.; Bilecka, I.; Textor, M.; Reimhult, E., Ultrastable Iron Oxide Nanoparticle Colloidal Suspensions Using Dispersants with Catechol-Derived Anchor Groups. *Nano Letters* 2009, 9, 4042-4048.

- 1  
2  
3  
4 29. Baccile, N.; Cuvier, A.-S.; Valotteau, C.; Van Bogaert, I. N. A., Practical Methods  
5 to Reduce Impurities for Gram-Scale Amounts of Acidic Sophorolipid Biosurfactants.  
6 Eur. J. Lipid Sci. Technol. 2013, 115, 1404-1412.  
7  
8  
9 30. Dhasaiyan, P.; Le Griel, P.; Roelants, S.; Redant, E.; Van Bogaert, I. N. A.;  
10 Prevost, S.; Prasad, B. L. V.; Baccile, N., Micelles Versus Ribbons: How Congeners  
11 Drive the Self-Assembly of Acidic Sophorolipid Biosurfactants. Chem. Phys. Chem.  
12 2017, 18, 643-652.  
13  
14  
15 31. Napolitano, A.; D'Ischia, M.; Costantini, C.; Prota, G., A New Oxidation Pathway  
16 of the Neurotoxin 6-Aminodopamine. Isolation and Characterization of a Dimer with a  
17 Tetrahydro[3,4a]Iminoethanophenoxazine Ring System. Tetrahedron 1992, 48, 8515-  
18 8522.  
19  
20  
21  
22 32. Bixner, O.; Lassenberger, A.; Baurecht, D.; Reimhult, E., Complete Exchange of  
23 the Hydrophobic Dispersant Shell on Monodisperse Superparamagnetic Iron Oxide  
24 Nanoparticles. Langmuir 2015, 31, 9198-9204.  
25  
26  
27 33. El-Faham, A.; Funosas, R. S.; Prohens, R.; Albericio, F., Comu: A Safer and  
28 More Effective Replacement for Benzotriazole-Based Uronium Coupling Reagents.  
29 Chem. - Eur. J. 2009, 15, 9404-9416.  
30  
31  
32 34. Kurzhals, S.; Zirbs, R.; Reimhult, E., Synthesis and Magneto-Thermal Actuation  
33 of Iron Oxide Core-Pnlpam Shell Nanoparticles. ACS App. Mater. Interfaces 2015, 7,  
34 19342-19352.  
35  
36  
37 35. Hyeon, T.; Lee, S. S.; Park, J.; Chung, Y.; Na, H. B., Synthesis of Highly  
38 Crystalline and Monodisperse Maghemite Nanocrystallites without a Size-Selection  
39 Process. J. Am. Chem. Soc. 2001, 123, 12798-12801.  
40  
41  
42 36. Park, J.; An, K.; Hwang, Y.; Park, J.-G.; Noh, H.-J.; Kim, J.-Y.; Park, J.-H.;  
43 Hwang, N.-M.; Hyeon, T., Ultra-Large-Scale Syntheses of Monodisperse Nanocrystals.  
44 Nat. Mater. 2004, 3, 891-895.  
45  
46  
47 37. Mondini, S.; Ferretti, A. M.; Puglisi, A.; Ponti, A., Pebbles and Pebblejuggler:  
48 Software for Accurate, Unbiased, and Fast Measurement and Analysis of Nanoparticle  
49 Morphology from Transmission Electron Microscopy (TEM) Micrographs. Nanoscale  
50 2012, 4, 5356-5372.  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

- 1  
2  
3  
4 38. Guinier, A.; Fournet, G., *Small-Angle Scattering of X-Rays*. John Wiley and Sons:  
5 New York, 1955.  
6  
7 39. <http://www.sasview.org>.  
8  
9 40. Finger, L. W.; Hazen, R. M.; Hofmeister, A. M., *High-Pressure Crystal Chemistry*  
10 *of Spinel (MgAl<sub>2</sub>O<sub>4</sub>) and Magnetite (Fe<sub>3</sub>O<sub>4</sub>): Comparisons with Silicate Spinel*s. *Phys.*  
11 *Chem. Miner.* 1986, 13, 215-220.  
12  
13 41. Gulley-Stahl, H.; Hogan, P. A., 2nd; Schmidt, W. L.; Wall, S. J.; Buhrlage, A.;  
14 Bullen, H. A., *Surface Complexation of Catechol to Metal Oxides: An ATR-FTIR,*  
15 *Adsorption, and Dissolution Study*. *Environ. Sci. Technol.* 2010, 44, 4116-4121.  
16  
17 42. Valotteau, C.; Calers, C.; Casale, S.; Berton, J.; Stevens, C. V.; Babonneau, F.;  
18 Pradier, C.-M.; Humblot, V.; Baccile, N., *Biocidal Properties of a Glycosylated Surface:*  
19 *Sophorolipids on Au(111)*. *ACS Appl. Mater. Interfaces* 2015, 7, 18086-18095.  
20  
21 43. Slovetskii, V. I., *Ir Spectra of Nitro Compounds*. *Bull. Acad. Sci. USSR, Div.*  
22 *Chem. Sci.* 1970, 19, 2086-2091.  
23  
24 44. Shirmardi Shaghasemi, B.; Dehghani, E. S.; Benetti, E. M.; Reimhult, E., *Host-*  
25 *Guest Driven Ligand Replacement on Monodisperse Inorganic Nanoparticles*.  
26 *Nanoscale* 2017, 9, 8925-8929.  
27  
28 45. Santos-Carballal, D.; Roldan, A.; Grau-Crespo, R.; de Leeuw, N. H., *A Dft Study*  
29 *of the Structures, Stabilities and Redox Behaviour of the Major Surfaces of Magnetite*  
30 *Fe<sub>3</sub>O<sub>4</sub>*. *Phys. Chem. Chem. Phys.* 2014, 16, 21082-21097.  
31  
32 46. Valotteau, C.; Banat, I. M.; Mitchell, C. A.; Lydon, H.; Marchant, R.; Babonneau,  
33 F.; Pradier, C.-M.; Baccile, N.; Humblot, V., *Antibacterial Properties of Sophorolipid-*  
34 *Modified Gold Surfaces against Gram Positive and Gram Negative Pathogens*. *Colloids*  
35 *Surf. B* 2017, 157, 325-334.  
36  
37 47. Chen, M.; Dong, C.; Penfold, J.; Thomas, R. K.; Smyth, T. J. P.; Perfumo, A.;  
38 Marchant, R.; Banat, I. M.; Stevenson, P.; Parry, A.; Tucker, I.; Campbell, R. A.,  
39 *Adsorption of Sophorolipid Biosurfactants on Their Own and Mixed with Sodium*  
40 *Dodecyl Benzene Sulfonate, at the Air/Water Interface*. *Langmuir* 2011, 27, 8854-8866.  
41  
42 48. Baccile, N.; Selmane, M.; Le Griel, P.; Prevost, S.; Perez, J.; Stevens, C. V.;  
43 Delbeke, E.; Zibek, S.; Guenther, M.; Soetaert, W.; Van Bogaert, I. N. A.; Roelants, S.,  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3  
4 Ph-Driven Self-Assembly of Acidic Microbial Glycolipids. *Langmuir* 2016, 32, 6343-  
5 6359.

6  
7 49. Abel, S.; Dupradeau, F.-Y.; Raman, E. P.; MacKerell, A. D.; Marchi, M.,  
8  
9 Molecular Simulations of Dodecyl-B-Maltoside Micelles in Water: Influence of the  
10 Headgroup Conformation and Force Field Parameters. *J. Phys. Chem. B* 2011, 115,  
11 487-499.

12  
13  
14 50. Bergin, R.; Carlstrom, D., Structure of the Pyrocatecholamines. li. Crystal  
15 Structure of Dopamine Hydrochloride. *Acta Crystallogr., Sect. B* 1968, 24, 1506-1510.

16  
17 51. Smith, M. B.; McGillivray, D. J.; Genzer, J.; Loesche, M.; Kilpatrick, P. K.,  
18  
19 Neutron Reflectometry of Supported Hybrid Bilayers with Inserted Peptide. *Soft Matter*  
20 2010, 6, 862-865.

21  
22  
23 52. Reimhult, E.; Schroffenegger, M.; Lassenberger, A., Design Principles for  
24 Thermo-responsive Core-Shell Nanoparticles – Controlling Thermal Transitions by Brush  
25 Morphology. *Langmuir* 2019, 22, 7092-7104

26  
27  
28 53. Manet, S.; Cuvier, A.-S.; Valotteau, C.; Fadda, G. C.; Perez, J.; Karakas, E.;  
29  
30 Abel, S.; Baccile, N., Structure of Bolaamphiphile Sophorolipid Micelles Characterized  
31 with SAXS, SANS, and MD Simulations. *J. Phys. Chem. B* 2015, 119, 13113-13133.

32  
33 54. Penfold, J.; Chen, M.; Thomas, R. K.; Dong, C.; Smyth, T. J.; Perfumo, A.;  
34  
35 Marchant, R.; Banat, I. M.; Stevenson, P.; Parry, A.; Tucker, I.; Grillo, I., Solution Self-  
36 Assembly of the Sophorolipid Biosurfactant and Its Mixture with Anionic Surfactant  
37 Sodium Dodecyl Benzene Sulfonate. *Langmuir* 2011, 27, 8867-8877.

38  
39  
40 55. Amstad, E.; Gillich, T.; Bilecka, I.; Textor, M.; Reimhult, E., Ultrastable Iron Oxide  
41 Nanoparticle Colloidal Suspensions Using Dispersants with Catechol-Derived Anchor  
42 Groups. *Nano Letters* 2009, 9, 4042-4048.

43  
44  
45 56. Zirbs, R.; Lassenberger, A.; Vonderhaid, I.; Kurzhals, S.; Reimhult, E., Melt-  
46 Grafting for the Synthesis of Core-Shell Nanoparticles with Ultra-High Dispersant  
47 Density. *Nanoscale* 2015, 7, 11216-11225.

48  
49  
50 57. Ikeda, Y.; Sunakawa, T.; Tsuchiya, S.; Kondo, M.; Okamoto, K., Toxicological  
51 Studies on Sophorolipid Derivatives. (I). Acute Toxicity, Eye Irritation, Primary Skin  
52 Irritation, Skin Sensitization, Phototoxicity, Photosensitization, Mutagenicity of  
53  
54  
55

1  
2  
3  
4 Polyoxypropylene (12) [(2'-O-Beta-D-Glucopyranosyl-Beta-D-Glucopyranosyl)Oxy-]  
5 Fatty Acid Ester-]. J. toxicol. Sci. 1986, 11, 197-211.

6  
7 58. Gal, N.; Lassenberger, A.; Herrero-Nogareda, L.; Scheberl, A.; Charwat, V.;  
8 Kasper, C.; Reimhult, E., Interaction of Size-Tailored PEGylated Iron Oxide  
9 Nanoparticles with Lipid Membranes and Cells. ACS Biomat. Sci. Eng. 2017, 3, 249-  
10 259.

11  
12  
13  
14 59. Varela-Aramburu, S.; Wirth, R.; Lai, C. H.; Orts-Gil, G.; Seeberger, P. H.,  
15 Straightforward and Robust Synthesis of Monodisperse Surface-Functionalized Gold  
16 Nanoclusters. Beilstein J. Nanotech. 2016, 7, 1278-1283.

17  
18  
19 60. Reynolds, M.; Marradi, M.; Imberty, A.; Penades, S.; Perez, S., Influence of  
20 Ligand Presentation Density on the Molecular Recognition of Mannose-Functionalised  
21 Glyconanoparticles by Bacterial Lectin Bc2I-A. Glycoconj. J. 2013, 30, 747-757.

22  
23  
24 61. Ruiz, C. C., Sugar-Based Surfactants; Fundamentals and Applications. [In:  
25 Surfactant Sci. Ser., 2009; 143]. CRC Press: 2008.

## Graphical Abstract

